INTELLIGENT BIO SOLUTIONS IN (INBS)
US36151G6008 - Common Stock
Overall INBS gets a fundamental rating of 4 out of 10. We evaluated INBS against 191 industry peers in the Health Care Equipment & Supplies industry. INBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INBS is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
INBS had negative earnings in the past year.
INBS had a negative operating cash flow in the past year.
In the past 5 years INBS always reported negative net income.
INBS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
INBS has a worse Return On Assets (-88.84%) than 80.95% of its industry peers.
The Return On Equity of INBS (-170.65%) is worse than 74.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -88.84% | ||
| ROE | -170.65% | ||
| ROIC | N/A |
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INBS's Gross Margin of 48.31% is in line compared to the rest of the industry. INBS outperforms 41.80% of its industry peers.
The Profit Margin and Operating Margin are not available for INBS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
INBS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for INBS has been increased compared to 5 years ago.
Compared to 1 year ago, INBS has an improved debt to assets ratio.
2.2 Solvency
INBS has an Altman-Z score of -8.51. This is a bad value and indicates that INBS is not financially healthy and even has some risk of bankruptcy.
INBS's Altman-Z score of -8.51 is on the low side compared to the rest of the industry. INBS is outperformed by 77.25% of its industry peers.
INBS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.51 |
ROIC/WACCN/A
WACC8.92%
2.3 Liquidity
INBS has a Current Ratio of 1.14. This is a normal value and indicates that INBS is financially healthy and should not expect problems in meeting its short term obligations.
INBS has a Current ratio of 1.14. This is amonst the worse of the industry: INBS underperforms 88.36% of its industry peers.
INBS has a Quick Ratio of 1.01. This is a normal value and indicates that INBS is financially healthy and should not expect problems in meeting its short term obligations.
INBS has a worse Quick ratio (1.01) than 76.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.06%, which is quite impressive.
Looking at the last year, INBS shows a very strong growth in Revenue. The Revenue has grown by 55.29%.
INBS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 589.28% yearly.
EPS 1Y (TTM)75.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.36%
Revenue 1Y (TTM)55.29%
Revenue growth 3Y16.25%
Revenue growth 5Y589.28%
Sales Q2Q%9.53%
3.2 Future
The Earnings Per Share is expected to grow by 44.75% on average over the next years. This is a very strong growth
INBS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.78% yearly.
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
INBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
INBS is valuated cheaply with a Price/Forward Earnings ratio of 3.64.
99.47% of the companies in the same industry are more expensive than INBS, based on the Price/Forward Earnings ratio.
INBS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.53.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.64 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INBS's earnings are expected to grow with 44.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for INBS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTELLIGENT BIO SOLUTIONS IN
NASDAQ:INBS (1/14/2025, 8:00:02 PM)
Premarket: 1.32 +0.02 (+1.54%)1.3
-0.02 (-1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners14.38%
Inst Owner Change0%
Ins Owners1.27%
Ins Owner Change15.24%
Market Cap5.71M
Analysts85.71
Price Target12.24 (841.54%)
Short Float %10.03%
Short Ratio3.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-93.54%
Min EPS beat(2)-157.59%
Max EPS beat(2)-29.49%
EPS beat(4)1
Avg EPS beat(4)-52.71%
Min EPS beat(4)-157.59%
Max EPS beat(4)37.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-50.63%
Min Revenue beat(2)-51.15%
Max Revenue beat(2)-50.1%
Revenue beat(4)0
Avg Revenue beat(4)-39.76%
Min Revenue beat(4)-51.15%
Max Revenue beat(4)-25.68%
Revenue beat(8)0
Avg Revenue beat(8)-35.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.64 | ||
| P/S | 1.79 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.93 | ||
| P/tB | 3.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.54
EYN/A
EPS(NY)0.36
Fwd EY27.46%
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.73
BVpS1.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -88.84% | ||
| ROE | -170.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.31% | ||
| FCFM | N/A |
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | -8.51 |
F-Score5
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.36%
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)55.29%
Revenue growth 3Y16.25%
Revenue growth 5Y589.28%
Sales Q2Q%9.53%
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.58%
OCF growth 3YN/A
OCF growth 5YN/A